GM's recent success puts pressure on Tesla as it fights to maintain its EV dominance ahead of today…

The spotlight is on earnings season after a surprise jobs report called into question when the next…

Moderna lowered its annual sales forecast as sales of its COVID-19 vaccine dropped by 37%, fueled b…

The rollout of the vaccine has already led to a substantial financial windfall for the New York …

Fourth-quarter consensus EPS is now tracking 6% above where it stood on January 1, which is higher …

India’s benchmark indices Sensex and Nifty50 were flat in morning trade on Tuesday amidst positive …

Moderna now anticipates full-year production between 700 million and 800 million doses, a downgrade…

Pfizer said it expects $26 billion in revenue from its coronavirus shot in 2021, up $11 billion fro…

The company now expects vaccine revenues of around $26 billion, 73% higher than initially projected.

Musk called for Harvard's defunding this week, amidst the backlash toward president Claudine Gay ov…

Vaccine demand is likely to persist well into next year, the company said, with more than a billion…

US stocks dropped at the open Tuesday as the economic reopening trade lost steam and major airline …

The drugmaker expects to earn $36 billion from vaccine sales by the end of 2021, compared to $41.9 …

More than 80% of S&P 500 firms that have reported earnings so far have beaten analyst expectations,…

The number of job openings in June dropped by more than expected, according to data from the Labor …

Pfizer expects to supply up to 1.3 billion doses of its shot in 2021, while Moderna expects to manu…

The drugmaker expects 2022 revenue of $98 billion to $102 billion, which fell below analyst expecta…

Pfizer will sell 23 drugs used to treat infectious and inflammatory diseases, cancers, and coronavi…

Pfizer cleared a massive resistance level last week when it surged above its record high of $47.39 …

Shares of Pfizer jumped to a high of $48.57 on Tuesday, more than a dollar higher than its previous…